Actively Recruiting
Long-Term Follow-Up Study to Evaluate Safety and Efficacy of YCANTH (VP-102/TO-208) in People With Common Warts
Led by Verrica Pharmaceuticals Inc. · Updated on 2026-05-05
600
Participants Needed
4
Research Sites
3 weeks
Total Duration
On this page
Sponsors
V
Verrica Pharmaceuticals Inc.
Lead Sponsor
A
Allucent (US) LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the long-term safety and effectiveness of a treatment called YCANTH (also known as VP-102 or TO-208) for people with common warts who previously participated in related studies (COVE-2 or COVE-3). This phase 3, open-label study aims to monitor side effects, including expected local skin reactions, and to assess how well repeated applications of YCANTH clear common warts over time. Participants with warts at the start of the study will receive YCANTH applied directly to each wart every 21 days, up to four additional treatments or until all warts clear. After clearance, participants will have observation visits every 42 days without treatment, but if new warts appear, treatment will resume. The study includes careful wart preparation, application of the drug with occlusive tape overnight, and monitoring of skin reactions. The entire study lasts approximately 294 days from parent study completion to the final visit on Day 378. Throughout the study, participants will attend treatment and observation visits where researchers will evaluate wart clearance, skin reactions, vital signs, and medication use. Detailed assessments include wart counts, photographic documentation for those who consent, and monitoring for adverse events. Participants must follow study instructions, including limiting certain water exposures after treatment, and will be observed until the study ends on Day 378.
CONDITIONS
Brief Title
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Completed Day 84, 105, or 147 visit in the parent study with at least one treatable common wart (except Day 147 completion without warts)
- Provided written informed consent or assent with parent/guardian consent if applicable
- Agree to avoid swimming, bathing, or prolonged water immersion until study drug removal after treatment
- Able and willing to follow study instructions and complete all requirements
- Agree not to use other wart-removing products during the study except for allowed destructive therapies for excluded wart types
- Provided written authorization for use and disclosure of protected health information
- Agree to optional photographic assessment if participating
You will not qualify if you...
- Unable to cooperate with study requirements or visits
- Unwilling to treat any warts in allowed locations
- Systemically immunosuppressed or used systemic immunosuppressive medication within 30 days prior or planned during study
- Have chronic or acute medical conditions interfering with study or increasing risk (e.g., HIV, lupus, hepatitis, uncontrolled diabetes)
- Received any treatment for common warts, including investigational agents, within 30 days before treatment
- Received immunizations within 5 days before or after study drug treatment
- Received investigational products unrelated to common warts within 30 days before study drug application
- Have epidermodysplasia verruciformis
- Have active malignancy or undergoing cancer treatment
- Have significant medical, psychiatric, or emotional conditions affecting safety or data quality
- Hypersensitivity to YCANTH or related compounds
- Conditions interfering with participation (e.g., hospitalization, substance abuse)
- Sexually active or may become sexually active and unwilling to use responsible birth control; females must have negative pregnancy tests before treatment
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Duration - Up to 12 weeks
Participants receive cantharidin applied to treatable common warts using a single-use applicator. Occlusive tape is applied to the treated area to maximize adherence. Treatment visits may occur up to four times.
Up to 4 treatment visits
Duration - Up to Day 378 from the end of treatment
Participants are followed for safety and efficacy assessments after treatment, including monitoring adverse events, vital signs, concomitant medication use, and wart clearance.
Periodic follow-up visits until Day 378
Trial Site Locations
Total: 4 locations
1
Florida Center for Dermatology, P.A.
Saint Augustine, Florida, United States, 32080
Actively Recruiting
2
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, United States, 46168
Actively Recruiting
3
Optima Research Boardman
Boardman, Ohio, United States, 44512
Actively Recruiting
4
Texas Dermatology
San Antonio, Texas, United States, 78235
Actively Recruiting
Research Team
P
Project Manager
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here